Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » SMARTag Technology: Better Conjugates

SMARTag Technology: Better Conjugates

Summary: Jennifer Mitcham describes how Catalent’s SMARTag technlogy combines the targeted binding specificity and half-life benefits of monoclonal antibodies with the potency advantages of small molecule chemotherapy or therapeutic agents.

The technology can overcome the limitations associated with conventional protein chemistries that produce heterogeneous products with variable conjugate potency, toxicity and stability.

She goes on to discuss new uses for ADCs.